Dimerix Limited · ASX:DXB
Dimerix — Canaccord Drug & Device Conference 2025
13 slides from Dimerix's conference presentation, Oct 21, 2025
Slide 1: Dimerix presents at Canaccord Drug & Device 2025 Conference
For Immediate Release DIMERIX PRESENTS AT CANACCORD DRUG & DEVICE 2025 CONFERENCE MELBOURNE, Australia, 21 October 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will
Slide 2: About DMX-200, FSGS and the Phase 3 study
About DMX-200 DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032,
Slide 3: Developing new therapies to treat inflammatory causes of kidney disease
For personal use only Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs Investor Presentation October 2025 Authorised for lodgement by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. For personal use only Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that th
Slide 5: Overview: Phase 3 DMX-200, FSGS opportunity and licensing
Overview Phase 3 Global Opportunity For personal use only Lead drug candidate FSGS indication a rare disease that No approved treatments Orphan drug designation 4 ~$1.4 billion in total upfront & >$65 million DMX-200 in a Phase causes scar tissue available to treat regulatory, potential in total pay
Slide 6: Cycle of damage in glomerular diseases
Cycle of damage : in glomerular diseases Existing blood pressure medication What is FSGS? For personal use only Kidney vessels have to work harder under high pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration Glomerulo = of the kidney filtering units with
Slide 7: Measuring kidney damage – surrogate endpoints
Measuring kidney damage – surrogate endpoints 1. Estimated glomerular filtration rate (eGFR) 2. Proteinuria For personal use only Treatments, such as DMX-200, aim to bring the FSGS slope back up: • A healthy kidney is a good filter and allows little to no protein • can add years to the life of the i
Slide 8: Phase 3 clinical trial
phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB ~286 257 59 For personal use only Total number of adult patients Patients recruited, randomised Patients enrolled over into required - anticip
Slide 9: Blinded analysis process
Blinded analysis process PARASOL collaboration: observational data analysis of major renal registries completed1,2 • results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024 For personal use only • potential relationship between proteinuria at 12 months a
Slide 10: FSGS commercial opportunity and pricing
Biopsy 7 per 1,000,000 FSGS is the most DMX-200 For personal use only frequent primary FSGS diagnosis driven by glomerular disease Commercial rates of biopsy - growth Global incidence rate of that reaches end-stage manufacturing sites potential as biopsy rates FSGS per capita per year1 renal failure
Slide 11: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Licensing deals collectively Dimerix has successfully partnered DMX-200 across key markets valued up to ~AU$1.4 billion For personal use only 1 2 3 4 in total upfront and potential milestone fees plus royalties1 United States EU, CA, AU, NZ GCC, Iraq Ja
Slide 12: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB For personal use only Cash Balance (Jun25) $68.3 million Market Capitalisation1 $312 million Share price1 $0.52 Total ordinary shares on issue1 600,184,606 Average Daily Liquidity by value for $1.03 million past 30 trading days2 S UBSTA N
Slide 13: Potential catalysts CY 2025
Potential catalysts CY 2025 1 2 3 For personal use only Q1/Q2 Q3/Q4 Potential 2025 2025 upside DMX-200 licensed in US for up to ➢ Outcome of PARASOL working group analysis received 8 ➢ Additional licensing partners for DMX- ~AU$940 million1 October 20255 200: Dimerix continues to pursue DMX-200 lice